Briacell Therapeutics Corp (BCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 07/31
| 10-2024 | 07-2024 | 04-2024 | 01-2024 | 10-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,829 | -4,932 | -3,683 | -5,375 | 5,959 |
| Depreciation Amortization | 27 | 84 | 12 | 8 | 4 |
| Accounts receivable | 365 | -733 | 4 | -11 | -3 |
| Accounts payable and accrued liabilities | -2,937 | 6,047 | 5,299 | 2,588 | -690 |
| Other Working Capital | -2,108 | 7,053 | 5,759 | 2,023 | 180 |
| Other Operating Activity | 3,527 | -31,646 | -27,481 | -14,239 | -13,056 |
| Operating Cash Flow | $-6,955 | $-24,126 | $-20,090 | $-15,007 | $-7,605 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -457 | N/A | N/A | N/A |
| Purchase Of Investment | -75 | -225 | -225 | N/A | N/A |
| Investing Cash Flow | $-75 | $-682 | $-225 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 11,960 | 4,419 | N/A | N/A | N/A |
| Financing Cash Flow | $11,960 | $4,419 | $N/A | $N/A | $N/A |
| Beginning Cash Position | 862 | 21,251 | 21,251 | 21,251 | 21,251 |
| End Cash Position | 5,792 | 862 | 936 | 6,245 | 13,646 |
| Net Cash Flow | $4,930 | $-20,389 | $-20,315 | $-15,007 | $-7,605 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,955 | -24,126 | -20,090 | -15,007 | -7,605 |
| Capital Expenditure | N/A | -457 | N/A | N/A | N/A |
| Free Cash Flow | -6,955 | -24,583 | -20,090 | -15,007 | -7,605 |